Latest News and Press Releases

Primary efficacy endpoint met with 95% reduction in gastrointestinal tissue eosinophils vs. 10% increase on placebo (p < 0.0001)Treatment response secondary endpoint met with 69% of AK002 treated...

REDWOOD CITY, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...

-- Substantial reduction of patient reported symptoms and physician assessed signs and symptoms -- -- Improvements also observed in atopic dermatitis, asthma and allergic rhinitis -- -- Conference...

REDWOOD CITY, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...

REDWOOD CITY, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...

-- 55% (6/11) response rate by UCT in Xolair Refractory CSU patients ---- 49% reduction in UAS7 in Xolair Refractory CSU patients -- -- 77% (10/13) complete hive response by HSS7 in Xolair Naïve CSU...

REDWOOD CITY, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...

-- 82% (9 of 11) response rate in patients with cholinergic urticaria ---- 70% (7 of 10) response rate in patients with symptomatic dermographism -- REDWOOD CITY, Calif., Jan. 29, 2019 (GLOBE...

-- 12 of 13 (92%) patients achieved a complete response -- -- Results from 3 additional cohorts expected in the first quarter of 2019 -- REDWOOD CITY, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) --...

-- Clinical data expected in early first quarter 2019 -- SAN CARLOS, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the...